Strategic partnerships Scailyte collaborates with clinical-stage biotech and pharma companies worldwide and has access to unique oncology and autoimmune patient cohorts, presenting opportunities for biomarker-driven drug development collaborations and joint ventures.

AI driven bio-signatures Leveraging the ScaiVision platform to analyze over 60 million single-cell profiles, Scailyte can offer validated biomarker signatures for patient stratification, companion diagnostics, and precision medicine trials.

Funding momentum Recent Innosuisse grant support and CHF 800k backing signal a strong validation and potential for co-funded research programs, appealing to partners seeking grant-aligned translational initiatives.

Leadership expansion New executive appointments and a dedicated Chief Business Officer indicate a push toward commercial partnerships, scalable business development, and faster time-to-market for biomarker solutions.

Market positioning Niche focus on single-cell omics biomarkers within oncology and auto-immunity, combined with patent-pending signatures, positions Scailyte as a specialized provider for biomarker discovery and precision medicine collaborations.